Related Experiment Videos
Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among
Amy E Miller1, Laura B Hansen, Joseph J Saseen
1Department of Pharmacy Practice, Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Pharmacotherapy
|May 2, 2008
Summary
A pharmacist-led therapeutic conversion program improved dyslipidemia control by increasing low-density lipoprotein (LDL) goal attainment. Usual care statin conversion led to decreased control, highlighting the benefit of proactive clinical pharmacist involvement in lipid-lowering drug management.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Atorvastatin was removed from the Colorado Indigent Care Program formulary.
- Dyslipidemia management requires effective statin therapy and monitoring.
Purpose of the Study:
- To compare the effectiveness of a therapeutic conversion program versus usual care for switching statin therapy.
- To evaluate the impact on low-density lipoprotein (LDL) cholesterol control.
Main Methods:
- Prospective cohort study involving 117 ambulatory care patients with dyslipidemia.
- Intervention group: Clinical pharmacists implemented a therapeutic conversion program using a specific algorithm.
- Usual care group: Medical providers switched statins based on a less structured approach.
Main Results:
- The therapeutic conversion group showed improved LDL goal attainment (80% to 97%).
- The usual care group experienced decreased LDL goal attainment (90% to 75%).
- Mean LDL concentrations showed no significant change in the therapeutic conversion group but increased in the usual care group.
Conclusions:
- A prospective, therapeutic statin conversion program significantly improved dyslipidemia control.
- Proactive clinical pharmacist involvement in converting lipid-lowering drugs leads to superior patient care outcomes.
- Usual care statin conversion was associated with decreased control of dyslipidemia.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:28IV Infusion to Oral Dosing: Conversion Methods
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...